Evidence map›Paper›PMID 18471804›Full record

ArticleBrain research2008

Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.

Nissar A Darmani, Yaozhi Wang, Joseph Abad, Andrew P Ray, Gerald R Thrush, Juan Ramirez

Open access · greenAbstract read
In one paragraph

Article in Brain research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. The Cannabinoid CBInternational journal of molecular sciences · 2025
    Article
  3. A Comparative Study of the Antiemetic Effects of αInternational journal of molecular sciences · 2024
    Article
  4. RNA sequencing least shrew (Frontiers in genetics · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. ΔEuropean journal of pharmacology · 2019
    Article
  15. Article
  16. Intracellular emetic signaling evoked by the L-type CaEuropean journal of pharmacology · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nissar A DarmaniDepartment of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA. ndarmani@westernu.edu
Yaozhi Wang
Joseph Abad
Andrew P Ray
Gerald R Thrush
Juan Ramirez
Western University of Health Sciences · US

Funding

MECHANISMS OF CANNABINOID'S ANTIEMETIC ACTIONSR01CA115331 · NCI · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI DARMANI, NISSAR A · 2004 to 2007
$695k
NCI NIH HHS R01 CA115331NCI NIH HHS R01CA115331
6 · The paper itself

Abstract

Substance P (SP) is thought to play a cardinal role in emesis via the activation of central tachykinin NK1 receptors during the delayed phase of vomiting produced by chemotherapeutics. Although the existing supportive evidence is significant, due to lack of an appropriate animal model, the evidence is indirect. As yet, no study has confirmed that emesis produced by SP or a selective NK1 receptor agonist is sensitive to brain penetrating antagonists of either NK1, NK2, or NK3 receptors. The goals of this investigation were to demonstrate: 1) whether intraperitoneal (i.p.) administration of either SP, a brain penetrating (GR73632) or non-penetrating (e.g. SarMet-SP) NK1 receptor agonist, an NK2 receptor agonist (GR64349), or an NK3 receptor agonist (Pro7-NKB), would induce vomiting and/or scratching in the least shrew (Cryptotis parva) in a dose-dependent manner; and whether these effects are sensitive to the above selective receptor antagonists; 2) whether an exogenous emetic dose of SP (50 mg/kg, i.p.) can penetrate into the shrew brain stem and frontal cortex; 3) whether GR73632 (2.5 mg/kg, i.p.)-induced activation of NK1 receptors increases Fos-measured neuronal activity in the neurons of both brain stem emetic nuclei and the enteric nervous system of the gut; and 4) whether selective ablation of peripheral NK1 receptors can affect emesis produced by GR73632. The results clearly demonstrated that while SP produced vomiting only, GR73632 caused both emesis and scratching behavior dose-dependently in shrews, and these effects were sensitive to NK1-, but not NK2- or NK3-receptor antagonists. Neither the selective, non-penetrating NK1 receptor agonists, nor the selective NK2- or NK3-receptor agonists, caused a significant dose-dependent behavioral effect. An emetic dose of SP selectively and rapidly penetrated the brain stem but not the frontal cortex. Systemic GR73632 increased Fos expression in the enteric nerve plexi, the medial subnucleus of nucleus tractus solitarius, and the dorsal motor nucleus of the vagus, but not the area postrema. Ablation of peripheral NK1 receptors attenuated the ability of GR73632 to induce a maximal frequency of emesis and shifted its percent animals vomiting dose-response curve to the right. The NK1-ablated shrews exhibited scratching behavior after systemic GR73632-injection. These results, for the first time, affirm a cardinal role for central NK1 receptors in SP-induced vomiting, and a facilitatory role for gastrointestinal NK1 receptors. In addition, these data support the validation of the least shrew as a specific and rapid behavioral animal model to screen concomitantly both the CNS penetration and the antiemetic potential of tachykinin NK1 receptor antagonists.

Indexed as

Neurokinin-1 Receptor AntagonistsAnimalsAntiemeticsBrainDisease Models, AnimalDose-Response Relationship, DrugDrug Evaluation, PreclinicalEnteric Nervous SystemOncogene Proteins v-fosPeptide FragmentsPiperidinesReceptors, Neurokinin-1Recombinant Fusion ProteinsRibosome Inactivating Proteins, Type 1SaporinsShrews3-(2-methoxybenzylamino)-2-phenylpiperidineAntiemeticsGR 73632Neurokinin-1 Receptor AntagonistsOncogene Proteins v-fosPeptide FragmentsPiperidinesReceptors, Neurokinin-1Recombinant Fusion ProteinsRibosome Inactivating Proteins, Type 1SaporinsSSP-SAP fusion protein, recombinantSubstance P

Identifiers

PMID18471804
PMCPMC2486262
OpenAlexW2045487778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.